The U.S. Government Accountability Office has confirmed the generation of an immune response in the first COVID-19 vaccine's human trial.
The antibody response to the vaccine in the high dose group was slightly greater than that in the middle dose and low dose groups.
Based on the results, the researchers have said that the vaccine was well tolerated by the volunteers at all doses with no serious adverse events reported within 28 days of vaccination.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.